AAV vector Archives - PharmaDeviceNews

GenSight Biologics begins LHON treatment under France compassionate access as REVISE Phase II moves forward

by Pallavi Madhiraju
March 21, 2026
0 Comments

GenSight Biologics begins treating ND4-LHON patients under France's AAC compassionate access program. Analyse what REVISE and AAC mean for the regulatory pathway.

Can AB-1009 reshape treatment for late-onset Pompe? AskBio prepares for first patient in U.S.

AskBio’s AB-1009 gene therapy for late-onset Pompe secures FDA IND clearance. Find out what this milestone means for AAV innovation and patient outlook.